Protalix (PLX) Shares Jump Following FDA Approval of ELELYSO, Co. to Host Call at 8am ET Wednesday
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $28.07 +1.01%
Financial Fact:
Provision for taxes on income: 284M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Provision for taxes on income: 284M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Pfizer Inc. (NYSE: PFE) and Protalix BioTherapeutics, Inc. (AMEX: PLX) announced today that the US FDA approved ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.
Protalix said it will host a conference call and webcast for Wednesday, May 2, 2012 at 8:00 AM EDT to review the U.S. Food and Drug Administration's approval of ELELYSO™ for the treatment of Type 1 Gaucher disease.
Protalix said it will host a conference call and webcast for Wednesday, May 2, 2012 at 8:00 AM EDT to review the U.S. Food and Drug Administration's approval of ELELYSO™ for the treatment of Type 1 Gaucher disease.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Nuvectis Pharma (NVCT) files $200M mixed shelf
- Kimbell Royalty closes $221.2M mineral rights acquisition
Create E-mail Alert Related Categories
Conference Calls, Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
